A novel drug-eluting stent appears to substantially improve outcomes for heart attack patients more than a bare-metal stent, researchers found. The risk of major cardiovascular adverse events over one year was 51% lower with the biodegradable polymer BioMatrix stent (4.3% versus 8.7%, P=0.004), Lorenz Räber, MD, of Bern University Hospital in Bern, Switzerland, and colleagues reported.
The evolution of anti-thrombotic strategies over time has resulted in a decrease in bleeding risk after percutaneous coronary intervention (PCI), researchers found. Examining the bleeding rates for both vascular access and anti-thrombotic strategies, the investigators reported that the nearly 20% reduction over time was largely due to temporal changes in anti-thrombotic strategies, according to their paper in the Journal of the American College of Cardiology.
APPOSITION III study results reveal mortality at 1.2% compared to 3.5% in pooled analysis of conventional stents. PRINCETON, N.J. & PARIS--(Healthcare Sales & Marketing Network)--STENTYS S.A. (STNT.PA), a medical technology company commercializing the world s first and only Self-Apposing® Stent to treat Acute Myocardial Infarction (AMI), announced today the definite results on the 1,000-patient APPOSITION III clinical study at one month after treatment of a severe heart attack.
Paris, France, 16 May 2012 – BioMatrix Flex™, Biosensors’ Biolimus A9™-eluting stent system with abluminal biodegradable polymer, has been chosen as the stent system for use in GLOBAL LEADERS, the largest ever randomized clinical trial involving a drug-eluting stent (DES). The latest plans for the trial were announced yesterday at EuroPCR by Study Chairman Professor Patrick W. Serruys.
Randomized Controlled Trial Results Presented At EuroPCR Demonstrate Advantages Over Uncoated Angioplasty Balloons and Drug-Eluting Stents
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that significant clinical data for its structural heart portfolio is being presented during EuroPCR. Among the highlights are first-in-man and six-month data for the company s Portico™ Transcatheter Aortic Heart Valve and results from a multicenter study for AMPLATZER™ Cardiac Plug (ACP) technology.
St. Jude Medical, Inc. (NYSE:STJ - News), a global medical device company, today announced that preliminary data demonstrated the company’s EnligHTN™ renal denervation system was safe and effective for the treatment of resistant hypertension. The study demonstrated that on average patients with resistant hypertension experience a systolic blood pressure reduction of 28 points after 30 days.
Transcatheter replacement of failing bioprosthetic aortic valves is usually successful but likely should be left to the most expert hands, researchers suggested. In a global registry of valve-in-valve procedures, 87.5% of the fairly high-risk cohort saw a reduction in symptom severity to New York Heart Association class I or II.
Boston Scientific Corporation (BSX) announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus™ Aortic Valve System in patients with severe aortic valve disease. The Lotus Aortic Valve System is the first transcatheter aortic valve replacement (TAVR) device of its kind that is designed to minimize aortic regurgitation (leaking) and is both fully repositionable and retrievable prior to release. Data presented today at the annual EuroPCR Scientific Program in Paris demonstrated successful deployment of the valve in all patients with virtually no paravalvular regurgitation after valve placement or at discharge.
Abbott (NYSE: ABT) today announced that the XIENCE PRIME and the XIENCE V® Everolimus Eluting Coronary Stent Systems have received CE Mark in Europe for the use of dual anti-platelet therapy (DAPT) for at least three months after stent implantation in patients with coronary artery disease. This is the shortest duration of DAPT for any major drug eluting stent (DES) in Europe.
Volcano Corporation (NASDAQ: VOLC) today announced its plans to highlight its extensive product portfolio, strong product pipeline, and presentations on Fractional Flow Reserve (FFR) and Instant Wave-Free Ratio Functionality (iFR) at EuroPCR 2012, a major cardiology meeting being held in Paris from May 15 18.
To reduce radiation dose while maintaining high image quality, Steinberg Diagnostic Medical Imaging Center (SDMI) in Las Vegas has installed the first AquilionTM PRIME 160 series from Toshiba America Medical Systems, Inc. in the U.S. Reinforcing the principle of As Low As Reasonably Achievable (ALARA), SDMI uses Adaptive Iterative Dose Reduction (AIDR) and NEMA XR 25 Dose Check Software to conduct a variety of general imaging exams while minimizing radiation dose. SDMI will soon be upgraded to Toshiba’s recently FDA-cleared AIDR 3D software to further enhance dose reduction and image quality.
BIOTRONIK Release: Twelve-Month ENERGY Registry Results of PRO-Kinetic Energy Passively Coated Stent Presented at the European Conference of Paris Course on Revascularization
Follow-up Data from EVOLVE Trial Presented at EuroPCR; Trial is Evaluating Next-Generation Everolimus-Eluting Platinum Chromium Coronary Stent with Ultra-Thin Bioabsorbable Abluminal Polymer.
St. Jude Medical PressureWire helped reduce the risk of urgent revascularization by more than eleven times in patients with stable coronary artery disease compared to medical treatment alone
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos